Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES Study.
Schlam I, Hirko KA, Shveid D, Abuali I, Sewaralthahab S, Nakhils F, Hazra A, Lengyel C, Altuna S, Hussain S, Seid F, Jamil S, Odhiambo A, Leone JP, Metzger O, Abraham J, Soto-Perez-de-Celis E, Chen WY, Block C, Schumer S, Bellon JR, Valenza C, Curigliano G, Tolaney SM, Lynce F, Trapani D. Schlam I, et al. JCO Glob Oncol. 2024 Dec;10:e2400307. doi: 10.1200/GO-24-00307. Epub 2024 Dec 20. JCO Glob Oncol. 2024. PMID: 39705637
Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA study.
Schlam I, Smith DM, Peer C, Sissung T, Schmidt KT, Tan M, Chitalia A, Bishopric NH, Steinberg S, Choo-Wosoba H, Napoli G, Gallagher C, Ashai N, Whitaker K, Mainor C, Tiwari S, Swanson N, Malloy S, Isaacs C, Figg WD, Swain SM. Schlam I, et al. NPJ Breast Cancer. 2024 Sep 30;10(1):84. doi: 10.1038/s41523-024-00692-w. NPJ Breast Cancer. 2024. PMID: 39349477 Free PMC article.
Pharmacokinetics and Pharmacogenomics of Ribociclib in Black Patients with Metastatic Breast Cancer: The LEANORA study.
Swain S, Schlam I, Smith DM, Peer C, Sissung T, Schmidt K, Tan M, Chitalia A, Bishopric N, Steinberg S, Choo-Wosoba H, Napoli G, Gallagher C, Ashai N, Whitaker K, Mainor C, Tiwari S, Swanson N, Malloy S, Isaacs C, Figg W. Swain S, et al. Among authors: schlam i. Res Sq [Preprint]. 2024 Aug 13:rs.3.rs-4656461. doi: 10.21203/rs.3.rs-4656461/v1. Res Sq. 2024. Update in: NPJ Breast Cancer. 2024 Sep 30;10(1):84. doi: 10.1038/s41523-024-00692-w PMID: 39184092 Free PMC article. Updated. Preprint.
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: schlam i. Nat Commun. 2024 May 10;15(1):3957. doi: 10.1038/s41467-024-48359-1. Nat Commun. 2024. PMID: 38730268 Free PMC article. No abstract available.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Among authors: schlam i. Nat Commun. 2024 Mar 27;15(1):2691. doi: 10.1038/s41467-024-46961-x. Nat Commun. 2024. PMID: 38538574 Free PMC article. Clinical Trial.
Best of the year: Advanced breast cancer in 2023.
Schlam I, Chavez-MacGregor M. Schlam I, et al. Breast. 2024 Apr;74:103677. doi: 10.1016/j.breast.2024.103677. Epub 2024 Feb 14. Breast. 2024. PMID: 38401422 Free PMC article. Review.
40 results